A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis

Exclusion Criteria

• •E01 Erythrodermic, guttate or pustular psoriasis
• •E02 Cardiac disease, including recent myocardial infarction, any degree of heart block or other cardiac arrhythmias or valvular heart disease
• •E03 Mania or acute delirium or epilepsy
• •E04 Narrow angle glaucoma
• •E05 Hyperthyroidism by medical history, TSH less than LLN, or a subject receiving thyroid medication
• •E06 Diabetes
• •E07 Intolerance to lidocaine
• •E08 Severe liver disease \[ALT laboratory value that exceeds 2.5x ULN\]
• •E09 Known severe kidney disease, acute urinary retention, prostatic hypertrophy with post void residual urine or laboratory value of creatinine that exceeds 1.5x ULN
• •E10 Significant gastrointestinal disease including but not limited to pyloric stenosis or paralytic ileus
• •E11 Inflammatory dermatoses except psoriasis; bacterial, viral, or fungal skin infections (at the test plaques); facial rosacea
• •E12 Active varicella, tuberculosis, syphilis or post-vaccine reactions
• •E13 Autoimmune disease other than plaque psoriasis (e.g., lupus erythematosis)
• •E14 Known allergic reactions or hypersensitivity to any of the components of the study treatments
• •E15 Allergy to adhesives on the templates used in this study
• •E16 UV therapy or significant UV exposure in the four weeks before treatment application
• •E17 History of malignancy (except for treated or excised basal cell carcinoma)
• •E18 History of drug or alcohol abuse (as defined by the Investigator)
• •E19 Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study
• •E20 Subject with demonstrated hypercalcemia (calcium greater than ULN) or evidence of Vitamin D toxicity
• •E21 Subject with demonstrated hypokalemia (less than LLN)